Geron To Present Six Abstracts At 68th American Society Of Hematology Annual Meeting
Benzinga Newsdesk 4 hours ago
News
Geron Corporation (Nasdaq: GERN), a hematology-focused commercial stage biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that six abstracts have been
Geron Corporation (Nasdaq: GERN), a hematology-focused commercial stage biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that six abstracts have been accepted for poster presentation at the 68th American Society of Hematology (ASH) Annual Meeting, to be held December 12-16, 2026, in New Orleans, LA. The presentations include new analyses providing further insight into the clinical activity and approved dosing regimen of RYTLEO® (imetelstat) in lower-risk myelodysplastic syndromes (LR-MDS).